Jilin Huisheng Biological Pharmaceutical Co., Ltd.

The main purpose of the study is to investigate the relative bioavailability of the single-dose oral (postprandial) test preparation dapagliflozin tablets (specification: 10 mg, applied for by Huisheng Biopharmaceutical Co., Ltd.) and the reference preparation dapagliflozin tablets (Andatang®, specification: 10 mg, produced by AstraZeneca Pharmaceuticals LP) in healthy Chinese subjects, analyze the pharmacokinetic parameters of the two preparations, evaluate the bioequivalence of the two preparations, and provide a reference for the application and clinical use of the drug. The secondary purpose of the study is to evaluate the safety of the test preparation and the reference preparation after a single oral administration in healthy Chinese subjects.